Johnson & Johnson (NYSE:JNJ) Sirturo Wins FDA Approval; First New TB Drug in Decades – JNJ, PFE, MRK, SNY

On Monday, the United States Food and Drug Administration reported that it has approved the New Brunswick, New Jersey based Johnson & Johnson (NYSE:JNJ) Sirturo for the treatment of multidrug resistant tuberculosis, the primary fresh medicine aimed at the disease in decades.

TB affected around 9 million people worldwide and around 11,000 in the United States previous year.

Director of the Office of Antimicrobial Products at the FDA Edward Cox reported that multi-drug resistant tuberculosis shows a serious health threat throughout the world and Sirturo offers much-required treatment for patients who do not have other therapeutic options available.

Shifting reader’s focus to broader market, let us consider market performance of other stocks that significantly affect same sector. Pfizer Inc. (NYSE:PFE) rose +0.76% to settle at $25.08, Merck & Co., Inc. (NYSE:MRK) moved up +0.74% to end at $40.94 while Sanofi SA (ADR) (NYSE:SNY) jumped +1.50% to finish at $47.38 on Monday.

Johnson & Johnson (NYSE:JNJ) last session’s volume of 12.77 million shares was higher than its average volume of 11.11 million shares. The stock after opening at $69.24 hit high price of $70.11 and then closed at $70.10 by scoring +0.89%.

JNJ generated revenue of $65.92 billion in the previous twelve months and earned $8.50 billion. The Company showed a positive 12.39% in the net profit margin as well as in its operating margin which remained at 16.68%. Company’s annual sales growth for the past five years was 4.05%.

The JNJ’s past twelve months’ price to sales ratio was 2.95 and price to cash ratio remained 9.83. As far as the returns are concerned, JNJ’s return on equity was recorded as 13.58% and return on investment increased 8.82% while its return on asset stayed at 7.08%.

The stock showed weekly downbeat performance of -0.24% which was maintained for the month at 1.27%. Likewise the positive performance for the quarter was recorded as 2.47% and for the year was 11.08% while the YTD performance remained at 10.85%.

DO NOT TRADE ANY STOCK WITHOUT LEVEL 2 STOCK QUOTES! delivers it's user with the most in-depth Level 2 Quotation System available on the Planet! NO Downloads, NO Widgets, NO Plugins required! Stay on TOP of your trades with! CLICK HERE TO START YOUR FREE 30-DAY TRIAL

This entry was posted in Healthcare, Latest Headlines and tagged , , , , , , , , , , , . Bookmark the permalink.